STAT3 and diffuse large B-cell lymphoma: Besides, WP1066, a STAT3 inhibitor, exhibited anti-cancer effects in multiple tumors [42, 43], including lymphoma [24], and we found WP1066 enhanced the inhibitory effects of AT56 on DLBCL progression.